Functional characterization of Fas ligand on tumor cells escaping active specific immunotherapy

Cell Death and Differentiation

Volumn 8, Issue 7, 2001, Pages 687-695

  Cefai D ^a   Schwaninger, R ^a   Balli, M ^a   Brunner, T ^a   Gimmi, C D ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Fas ligand; HER 2 neu; Immune escape; Tumor cell lines

Indexed keywords

FAS LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; ONCOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; GENE EXPRESSION; GENE FUNCTION; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; TARGET CELL; TUMOR CELL; TUMOR CELL LINE; TUMOR ESCAPE; TUMOR GROWTH; VACCINATION;

3T3 CELLS; ADENOCARCINOMA; ANIMALS; APOPTOSIS; COCULTURE TECHNIQUES; FAS LIGAND PROTEIN; FLOW CYTOMETRY; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY, ACTIVE; MAMMARY NEOPLASMS, ANIMAL; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; PHENOTYPE; RATS; RECEPTOR, ERBB-2; TUMOR CELLS, CULTURED; VACCINATION;

ANIMALIA;

EID: 0034915135     PISSN: 13509047     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cdd.4400862     Document Type: Article

References (42)

1. Relapse after successful treatment with immunotherapy: Lessons for the future
2. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas
3. Neoplastic cells that express low levels of MHC class I determinants escape host immunity
4. Timely immunization subverts the development of peripheral nonresponsiveness and suppresses tumor development in simian virus 40 tumor antigen-transgenic mice
5. Costimulation of T cells for tumor immunity
6. Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo?
7. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells
8. Escape from host-antitumor immunity
9. Melanoma cell expression of Fas (Apo-1/CD95) ligand: Implications for tumor escape
10. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand
11. Lymphocyte apoptosis induced by CD95 (Apo-1/Fas) ligand-expressing tumor cells - A mechanism of immune evasion?
12. The Fas counterattack in vivo: Apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma
13. Expression of Fas ligand in liver metastases of human colonic adenocarcinoma
14. Human lung carcinomas express Fas ligand
15. Expression of Fas ligand (CD95/APO-1) by human breast cancers: Significance for tumor privilege
16. CD95 ligand expression as a mechanism of immune escape in breast cancer
17. Fas-ligand is expressed in normal breast epithelial cells and is frequently upregulated in breast cancer
18. Expression of the apoptosis-inducing ligands FasL and TRIAL in malignant and benign human breast cancer
19. Fas counter-attack - The best form of tumor defense
20. Tumor counterattack-concept and reality
21. Gene transfer of Fas ligand induces tumor regression in vitro
22. Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts
23. Fas ligand expression in islets Langerhans does not confer immune privilege and instead targets them for rapid destruction
24. Antitumor effect of locally produced CD95 ligand
25. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene
26. Targeting HER-2/neu for active-specific immunotherapy in a mouse model of spontaneous breast cancer
27. The role of Fas ligand expression in promoting escape from immune rejection in an in vivo spontaneous tumor model
28. Technical Note: Aberrant detection of cell surface Fas ligand with anti-peptide antibodies
29. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family
30. The Jam test: A simple assay for DNA fragmentation and cell death
31. A modification of JAM test is necessary for correct determination of apoptosis induced FasL+ adherent tumor cells
32. Homeostasis and self-tolerance in the immune system: Turning lymphocytes off
33. A role for CD95 ligand in preventing graft rejection
34. Fas ligand-induced apoptosis as a mechanism of immune privilege
35. Human melanoma cells do not express Fas (Apo-1/CD95) ligand
36. Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape
37. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes
38. The tumor counterattack hypothesis revisited: Colon cancer cells do not induce T cell apoptosis via fas (CD95, APO-1) pathway
39. The role of the caspase family of cystein proteases in apoptosis
40. Regulation of proinflammatory effects of Fas ligand (CD95L)
41. neu and ras initiate murine mammary tumors that share genetic markers generally absent in c-myc and int-2 initiated tumors
42. Conversion of membrane-bound Fas (CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity